“Small to midsize biotechs are the future of the biopharma industry” says Stefan Verhayden, Global Vice President of GX biological solutions and syringes at Gerresheimer. Stefan leads the company’s packaging and drug delivery services in the fast growing biopharma segment.
“They are the ones develop molecules that then afterwards, either go commercial to themselves or are being picked up by the bigger biopharma companies that then will bring them to a commercial phase.”
In the latest episode of the PharmaSource podcast, he explains some of the challenges biopharma customers face, such as personalised medication.
Personalised and Sustainable bio drug delivery
Gerresheimer serve biotech customers throughout the complete value chain and drug lifecycle management – from preclinical development onwards.
“We see a clear trend towards more specialised medication, personalised medication. 80-90% of the new drugs that come to market are biological, and those customers face different challenges to small molecule drugs”
Gerresheimer is developing advanced technologies such as wearable devices that are used in some chronic diseases and oncology, linked to specific digital therapy follow-up.
Sustainability is another priority for the Gerresheimer business, which publicly signed up to Science Based Targets initiative with a goal of reducing CO2 emissions by 50% and switch their entire electricity supply to renewables by 2030.
The priority for 2024 is to “keep on focusing on our high value products and co-developing packaging solutions with industry colleagues” says Stefan. “For us, every customer is actually as unique as every project.
For more information visit the Gerresheimer website
Stay ahead of trends and best practices
